Aprepitant for PONV Prophylaxis in Outpatient Plastic Surgery
Status:
Completed
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
Hypothesis: Aprepitant plus ondansetron is more effective than ondansetron plus placebo for
prevention of postoperative emesis in patients at moderate-to-high risk for PONV for up to 48
hours after surgery.
Specific Aim: To determine the incidence of PONV during the first 48 hours after surgery; in
patients who have received aprepitant plus ondansetron versus ondansetron plus placebo for up
to 48 hours after surgery.